A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. (Q51385567)

From Wikidata

Jump to navigation Jump to search

scientific article published in December 2010

Language	Label	Description	Also known as
English	A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.	scientific article published in December 2010

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

pharmacodynamics

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Geoffrey J Parker

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Gordon C. Jayson

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Claire L Mitchell

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

J P B O'Connor

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

C Roberts

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Y Watson

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

S Cheung

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

J Evans

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

J Spicer

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

C Kelly

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

S Rudman

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

M Middleton

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

A Fielding

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

J Tessier

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

H Young

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

1 December 2010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

68

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

631-641

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

https://scigraph.springernature.com/pub.10.1007/s00280-010-1534-3

0 references

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1534-3

21 January 2018

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1534-3

21 January 2018

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1534-3

21 January 2018

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1534-3

21 January 2018

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1534-3

21 January 2018

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1534-3

21 January 2018

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1534-3

21 January 2018

Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1534-3

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1534-3

21 January 2018

Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1534-3

21 January 2018

Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1534-3

21 January 2018

Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1534-3

21 January 2018

Modeling tracer kinetics in dynamic Gd-DTPA MR imaging

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1534-3

21 January 2018

Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1534-3

21 January 2018

Key factors in the acquisition of contrast kinetic data for oncology

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1534-3

21 January 2018

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1534-3

21 January 2018

Identifiers

10.1007/S00280-010-1534-3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21120480%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51385567&oldid=2144513146"